中西医针药结合疗法治疗血管性痴呆的临床研究

目的:观察中西医针药结合疗法治疗血管性痴呆的临床疗效。方法:选取2020年1月—2021年7月河北北方学院附属第一医院收治的血管性痴呆病人120例,依据随机数字表法分为对照组、观察1组、观察2组,每组40例。对照组给予尼莫地平片、奥拉西坦胶囊治疗;观察1组给予尼莫地平片、奥拉西坦胶囊联合补肾活血祛瘀中药方剂治疗;观察2组给在观察1组基础上联合针灸治疗。使用简易智能精神状态检查量表(MMSE)及美国国立卫生研究院卒中量表(NIHSS)评价3组病人治疗前及治疗3个月后精神状态及神经功能缺损变化,并对比中医证候(SDSVD)积分变化;使用磁共振动脉自旋标记灌注成像(MRI-ASL)检查病人治疗前后局部脑血流量(rCBF);使用脑电图超慢涨落图(EFG)分析仪测定脑组织神经递质水平变化。结果:3组治疗前后NIHSS评分比较差异均无统计学意义(P>0.05)。3组治疗后MMSE评分较治疗前升高,SDSVD积分治疗前下降,rCBF值较治疗前升高,差异均有统计学意义(P<0.05);观察2组治疗后MMSE评分、rCBF值高于观察1组、对照组,SDSVD积分低于观察1组、对照组,差异均有统计学意义(P<0.05);3组治疗后脑内神经递质指标较治疗前明显改善(P<0.05),观察2组治疗后脑内神经递质指标改善程度较观察1组、对照组更为明显(P<0.05)。观察2组治疗总有效率为87.5%,高于观察1组(62.5%)、对照组(60.0%),差异均有统计学意义(P<0.05)。结论:中西医针药结合疗法可有效改善血管性痴呆病人精神状态,增加脑动脉局部脑血流量,提高脑组织神经递质水平及临床疗效。

针药中西医结合治疗和护理脑卒中痉挛性瘫痪临床效果研究

选择脑卒中后痉挛性瘫痪患者,对其治疗状况展开探究,以明确针药中西医结合方案的重要性。方法:收集我院脑卒中痉挛性瘫痪患者(2018年4月~2020年2月)病历资料,以药物治疗(巴氯芬片)为甲组(44例),以针药中西医结合方案为乙组(44例),借助Ashworth肌痉挛评定量表、Fugl-Mayer运动功能评分法、日常生活能力评定量表,评估患者肌痉挛改善程度、运动功能、日常生活活动能力,由此判断针药中西医结合方案的有效性、可行性。结果:治疗后,乙组肌痉挛改善程度高于甲组,P<0.05;乙组FMA评分、ADL评分高于甲组,78.33±15.19分vs58.15±11.03分、77.25±13.10分vs59.10±9.03分,P<0.05。结论:对进行常规护理的脑卒中痉挛性瘫痪患者辅以针药中西医结合治疗,可进一步提高机体整体康复效果,值得优选。

红藤紫金汤联合抗菌素治疗ICU多重耐药鲍曼不动杆菌肺炎45例

目的:通过观察红藤紫金汤联合抗菌素治疗ICU多重耐药鲍曼不动杆菌(acinetobacter baumannii,AB)肺炎的疗效,为本病治疗开拓新的方法与思路。方法:将90例符合纳入标准的多重耐药AB肺炎患者采用随机数字表法随机分为两组,对照组45例给予西药抗感染治疗,治疗组45例在对照组基础上联合口服自拟中药红藤紫金汤(红藤、紫花地丁、金银花、连翘、牡丹皮、清半夏、瓜蒌、浙贝母、大黄、败酱草、薏苡仁、赤芍、生地黄、柴胡、黄芩、炙甘草),1 d 1剂,水煎取汁400 mL,每次200 mL,每日2次,口服。两组均以14 d为1个疗程,1个疗程后判定疗效。结果:治疗组痊愈28例,显效10例,进步2例,无效5例,有效率为88.9%;对照组痊愈19例,显效7例,进步8例,无效11例,有效率为75.6%。两组对比,差别有统计学意义(P<0.05)。治疗组在降低患者血浆WBC、PCT、hs-CRP水平、细菌清除效果方面优于对照组(P<0.05,P<0.01)。结论:红藤紫金汤联合抗菌素能更好地降低血清各项炎症指标、清除AB,疗效优于单纯抗菌素治疗,值得临床推广运用。

醒脑静注射液联合纳络酮治疗急性安眠药中毒34例

目的:观察中西药联合治疗急性安眠药中毒的疗效。方法:将急性安眠药中毒患者65例,随机分为2组,治疗组34例采用醒脑静注射液联合纳络酮静滴,对照组31例单予纳络酮治疗,将2组疗效进行比较。结果:治疗组平均显效时间及平均治愈时间均较对照组明显缩短。结论:醒脑静注射液联合纳络酮治疗急性安眠药中毒疗效良好。

结核丸联合西药治疗耐多药肺结核的疗效观察

目的:探讨中西医结合治疗耐多药肺结核的疗效,为该病的有效治疗提供一定的理论参考依据。方法:以接收诊治的112例耐多药肺结核患者为研究对象,将其随机分为治疗组(56例)和对照组(56例)。治疗组56例患者进行中西医结合治疗,对照组56例患者进行单纯西医治疗,观察并记录不同给药的治疗效果以及患者的不良反应发生状况。结果:中西医结合治疗耐多药肺结核治疗组痰菌转阴率、中医症候有效率、病灶吸收有效率及临床症状改善情况均高于对照组患者。结论:采用中西医结合治疗耐多药肺结核提高了疗效,有效的降低了不良反应发生状况。

益母养肾生化汤联合西药治疗药物流产不全60例

目的:观察益母养肾生化汤联合西药治疗药物流产不全的临床疗效。方法:将90例药物流产患者采用随机数字表法随机分为治疗组60例和对照组30例,对照组于终止妊娠第1天晚8时首次口服米非司酮,50 mg/次;第2天早、晚8时各口服25 mg;第3天早8点口服25 mg后2 h顿服米索前列醇0.6 mg,服药前后空腹2 h。治疗组在第3天服用米索前列醇后加服中药益母养肾生化汤(黄芪、当归、川芎、丹参、桃仁、益母草、炮姜、仙茅、天花粉、怀牛膝、蒲黄、蒲公英、五灵脂、炙甘草),1 d 1剂,分2次口服。两组均以5 d为1个疗程,一般治疗1~2个疗程。结果:治疗组完全流产57例,不全流产3例,失败0例,完全流产率为95.0%;对照组完全流产20例,不全流产8例,失败2例,完全流产率为66.7%。两组疗效对比,差别有统计学意义(P<0.01)。结论:在药流成功率、缩短出血时间等方面,治疗组明显优于对照组,能够促进宫内残留物排出,减少出血量。

不同方法治疗抑郁症患者的疗效分析

目的:比较中药、西药、中西医结合药对抑郁症的治疗效果。方法:选取我院收治的抑郁症患者120例,随机分成中药组、西药组、中西医结合药组,每组40例。中药组服用清心安神颗粒,西药组服用氟西汀,中西医结合药组服用氟西汀,同时配合中药(随症加减),疗程6周,治疗结束后,比较三组患者的疗效。结果:中药组总有效率为75.0%,西药组总有效率为87.5%,中西医结合药组总有效率为97.5%。中西医结合药组总有效率明显高于中药组和西药组(P<0.05)。结论:中西医结合用药在治疗抑郁症方面有很好的疗效,效果优于中药或西药的单独治疗。

小儿重症肺炎治疗临床研究

目的探求治疗小儿重症肺炎的临床方法,以便有利于以后的临床治疗。方法选取2008年1月—2014年1月在我院治疗过的小儿重症肺炎感染者150例,随机的分为中药组、西药组、中西医结合组。对三组患者进行相应的治疗,即中药组使用中药清金理痰解毒方治疗;西药组使用多巴胺联合多巴酚丁胺进行治疗;中西医结合组则使用清金理痰解毒方联合西药阿奇霉素进行治疗,观察疗效。结果中医组患者中痊愈25例,有效10例,无效13例,死亡2例。西药组中痊愈35例,有效6例,无效9例,死亡0例。中西医结合组中痊愈43例,有效6例,无效1例,死亡0例。结论中西医结合治疗小儿重症肺炎整体效果优于单纯西药或者单纯中药的治疗。是值得推广的一种治疗方法。

A Comparative Analysis of the Administration of Oral Hypoglycemic Drugs in Second Affiliated Hospital of Guiyang Medical College during 2012-2014

[Objective] This study aimed to analyze the application and administration of oral hypoglycemic drugs in Second Affiliated Hospital of Guiyang Medical College,aiming at providing guidance and reference for clinical medication for treatment of diabetes.[Method] The main types,dosages and prices of oral hypoglycemic drugs in Second Affiliated Hospital of Guiyang Medical College during 2012-2014 were compared and analyzed using the computer network system.[Result] During 2012-2014,sales quantity and sales amount of oral hypoglycemic drugs in Second Affiliated Hospital of Guiyang Medical College demonstrated an upward trend.[Conclusion] Integrative medicine can significantly improve symptoms of diabetes complications.Certain achievements have been made in diabetes treatment by Second Affiliated Hospital of Guiyang Medical College.

COMPARATIVE STUDY ON THE THERAPEUTIC EFFECT OF ACUPUNCTURE AND WESTERN MEDICINES FOR TREATMENT OF PERIPHERAL FACIAL PALSY

Subjective: To observe the therapeutic effect of acupuncture in treatment of acute peripheral facial paralysis. Methods: A total of 80 cases of facial palsy were randomly divided into acupuncture group (n=50) and Western medicine (control) group (n=30). In acupuncture group, Cuanzhu (BL 2), Sibai (ST 2), Yangbai (GB 14), etc. were punctured, combined with TDP radiation, cupping or administration of Chinese medicinal herbs according to the concrete situations. Acupuncture treatment was given once daily, with 6 days being a therapeutic course, continuously for 4 courses. In control group, patients were treated with intravenous injection of “energy mixture”, dexamethasone, compound Danshen injectio, etc.. Results: After treatment, in acupuncture group, of the 50 cases, 48 were cured and 2 had improvement, with the effective rate being 100%; among them, 12 cases were cured in 7 days, 23 cured in 8～14 days, 10 cured in 15～21 days and 3 cured in 22～28 days. In control group, of the 30 cases, 19 were cured, 8 had improvement and 3 had no apparent changes, with the effective rate being 90%. Of the 19 cured cases, 5 were cured within 8～14 days, 10 cured in 15～21 days and 4 cured in 22～28 days. Conclusion: In treatment of acute periphery facial palsy, acupuncture is obviously superior to Western medicines in the therapeutic effect and cure duration.

Characteristics and Advantages of Traditional Chinese Medicine in the Treatment of Acute Myocardial Infarction

Objective: To obtain epidemiological data on Traditional Chinese Medicine (TCM) therapeutic status of acute myocardial infarction (AMI) and to determine TCM characteristics and advantages to improve the level of TCM prevention and treatment of AMI. Methods: Clinical epidemiology methods were used to register and survey the TCM therapeutic status of hospitalized AMI patients. In 2001, the Chinese Association of Integrative Medicine surveyed the therapeutic status of 3308 AMI patients hospitalized in 30 hospitals in Beijing and Shanghai from 2000-2001. The Beijing Collaborative Study Group on Therapeutic Status of Acute Myocardial Infarction (the Study Group) then conducted a 10-year-long register survey on hospitalized AMI patients in Third-grade A-Level TCM hospitals in Beijing. After 2002, the Study Group further surveyed the treatment conditions of AMI-hospitalized patients in 10 Second-grade A-Level TCM hospitals. The therapeutic status in 8 Third-grade A-Level Western medicine hospitals was surveyed in 2001 and 2005 as a control. In 2008, in cooperation with the China Association of Chinese Medicine, the Study Group further performed a survey at 26 Third-grade A-Level TCM hospitals nation-wide. Approximately 5000 cases were investigated to obtain authoritative data on the therapeutic status of AMI patients in TCM hospitals in China. Results: We found that Chinese herbal intravenous preparations may be beneficial in reducing the mortality of AMI. Major complications of AMI, such as heart failure and arrhythmia, were significantly less during the 10-year survey period. The mortality of hospitalized AMI patients showed a decline. TCM treatment was helpful for AMI patients in improving their quality of life. Ten-year dynamic monitoring showed that the ability to perform reperfusion and to use drugs appropriately, as well as an effort to carry out the Clinical Guidelines has made great progress in TCM hospitals. However, TCM hospitals still have some problems in treating AMI, including a lack of standardized TCM syndrome diagnosis, the need for syndrome differentiation and treatment standardization, and clinical skills in reperfusion and standardized drug treatment still need to be further improved. Compared with AMI patients in Western medicine hospitals during the same period, those in TCM hospitals had the following characteristics: they were admitted to hospital later; they were older when they had a heart attack; there were more females, they had more problems in their medical history, and they had more concomitant illnesses and complications. Therefore, the demographic baseline data were significantly different between AMI patients in TCM hospitals and those in Western medicine hospitals. This indicated that patients in TCM hospitals were more critical than those in Western medicine hospitals. Conclusions: TCM has special advantages in treating AMI. TCM hospitals are making continuous progress in standardized treatment of AMI, but further improvement is still required. AMI patients in TCM hospitals have some special characteristics, and their condition may be more critical. Further clinical research on TCM treatment of AMI is required.

Meta-analysis on integrative medicine for the treatment of malignant ascites: a comparative study

OBJECTIVE: To compare the efficacy of integrated Chinese and Western Medicine with that of only Western Medicine for the treatment of malignant ascites.METHODS: All randomized controlled trials(January 2004 to March 2013) from the China National Knowledge Infrastructure Database, Chinese Biomedical Literature Database, and Wanfang Database were searched with keywords. Meta-analysis was conducted by combining the odds ratios of the individual studies. Review Manager 5.0 was used for the analysis.RESULTS: One thousand one hundred and fifty-six patients from 19 randomized controlled trails were included. Of them, 630 patients were treated with integrated Chinese and Western Medicine(the integrative group), and 526 patients were treated with Western Medicine alone(the control group). The Meta-analysis showed that the total effective rate was 78.73% in the integrated group, and 59.13% in the control group. The effective percentage was sig-nificantly higher in the integrative group than that of the control group [OR = 2.85, 95% CI(2.16,3.74),P < 0.01].CONCLUSION: The short-term curative effect in the integrative group was better than that in the control group. Integrative medicine may be beneficial for malignant ascites.